Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial American Heart Journal Volume 163, Issue 1, Pages 33-38.e1 (January 2012) DOI: 10.1016/j.ahj.2011.10.003 Copyright © 2012 Mosby, Inc. Terms and Conditions
Figure 1 Flow diagram of the Pulmonary Embolism International Thrombolysis trial. RV indicates right ventricular (dysfunction); TNK, tenecteplase; VKA, vitamin K antagonists. *As defined in Table I; **criteria defined in Table I; †at a dosage of 80 IU/kg of body weight; ‡initial infusion rate, 18 IU/kg/h; §the dosing regimen for tenecteplase (or placebo) is shown in Table II. American Heart Journal 2012 163, 33-38.e1DOI: (10.1016/j.ahj.2011.10.003) Copyright © 2012 Mosby, Inc. Terms and Conditions